ZUCLOPENTHIXOL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H25ClN2OS
Molecular Weight	400.965
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC4=CC=C(Cl)C=C24)CC1

InChI

InChIKey=WFPIAZLQTJBIFN-DVZOWYKESA-N

InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-

HIDE SMILES / InChI

Description
Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf
Curator's Comment: Description was created based on several sources, including https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987

Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. Zuclopenthixol, a thioxanthene derivative, has high affinity for both dopamine D1 receptors and dopamine D2 receptors. Zuclopenthixol also has high affinity for α1-adrenergic and 5-HT2 receptors. Zuclopenthixol (CLOPIXOL®) is avavilable in the form of tablets and solution for intramuscular injections.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778
Dopamine D1 receptor 101 Target ID: CHEMBL2056 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778
Adrenergic receptor alpha-1 169 Target ID: CHEMBL2094251 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778
Serotonin 2 (5-HT2) receptor 87 Target ID: CHEMBL2093870 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26624987 http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf	Primary		Approved 8429	CLOPIXOL Approved Use Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness.
Bipolar disorder, manic phase 6 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf	Primary		Approved 8429	CLOPIXOL Approved Use Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness.

PubMed

Title	Date	PubMed
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.	1967	4383787
Prolonged oculogyric crisis on addition of nifedipine to neuroleptic medication regime.	1987 Jan	3651662
Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.	1987 Jul	3615572
[acute dystonias in combined abuse of cocaine and neuroleptics].	1994 Nov 26	7990989
Effect of some psychotropic drugs and a barbiturate on mycoplasmas.	2000 Apr	10773494
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.	2001 Jul	11549212
Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats.	2004 Aug	15497819
Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine.	2010 Apr	20175668

Patents

Sample Use Guides

In Vivo Use Guide

Clopixol tablets: The usual dose is 10 to 50 mg per day. Clopixol Acuphase injection: The usual dose is 50 to 150 mg (1 to 3 mL) every 2 to 3 days or as instructed by your doctor. Clopixol Depot injection: The usual dose is 200 to 400 mg (1 to 2 mL) every second to fourth week.

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

ZUCLOPENTHIXOL

Official Name

English

CLOPENTHIXOL CIS(Z)-FORM [MI]

Common Name

English

zuclopenthixol [INN]

Common Name

English

CLOPENTHIXOL CIS(Z)-FORM

Common Name

English

Zuclopenthixol [WHO-DD]

Common Name

English

ZUCLOPENTHIXOL [MART.]

Common Name

English

CLOPIXOL

Brand Name

English

Classification Tree Code System Code

WHO-ATC

N05AF05